De Novo Absence Status Epilepticus as a Benzodiazepine Withdrawal Syndrome
- 1 March 1993
- Vol. 34 (2) , 355-358
- https://doi.org/10.1111/j.1528-1157.1993.tb02421.x
Abstract
Summary: A 67‐year‐old woman with a history of psychotropic drug abuse developed confusion. EEG was consistent with absence status epilepticus (AS). Intravenous (i.v.) flumazenil 1 mg, a benzodiazepine antagonist with anticonvulsant properties, increased both confusion and paroxysmal activity. Complete resolution was obtained after diazepam was administered i.v., and the patient then admitted that she had abruptly discontinued long‐standing treatment with carpipramine, amitryptiline, bromazepam, and flunitrazepam. The aggravating effect of flumazenil indicates that benzodiazepine withdrawal was probably the elective triggering factor of this de novo absence status epilepticus.Keywords
This publication has 11 references indexed in Scilit:
- 'De novo' absence status of late onsetNeurology, 1992
- The effect of intravenous flumazenil on interictal electroencephalographic epileptic activity: results of a placebo-controlled study.Journal of Neurology, Neurosurgery & Psychiatry, 1991
- Feasibility of reversing benzodiazepine tolerance with flumazenilThe Lancet, 1991
- Diazepam and Ro 15-1788 increase absence epilepsy in WAG/Rij rats chronically exposed to diazepamEuropean Journal of Pharmacology, 1990
- Death after flumazepil.BMJ, 1989
- FlumazenilDrugs, 1988
- Acute Confusional State with Status Petit Mal as a Withdrawal Syndrome — and Five Year Follow-upThe Canadian Journal of Psychiatry, 1988
- Toxic ictal confusionJournal of Epilepsy, 1988
- The Anticonvulsant Effect of the Benzodiazepine Antagonist, Ro 15–1788: An EEG Study in 4 CasesEuropean Neurology, 1984
- Precipitated Withdrawal by a Benzodiazepine Receptor Antagonist (Ro 15-1788) After 7 Days of DiazepamScience, 1982